Registration - In-house Corporation

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Country President

Registration Information

In-house Corporation name: Novartis Pharmaceuticals Canada Inc.
Responsible Officer Name: Mark Vineis, Country President
Responsible Officer Change History
Initial registration start date: 2007-07-13
Registration status: Active
Registration Number: 957165-15599

Associated Communications

Total Number of Communication Reports: 91

Monthly communication reports in the last 6 months: 7

Version 38 of 38 (2024-05-01 to present)

Registration versions:

Version 38 of 38 (2024-05-01 to present)

Lobbying Information

Subject Matter Details

Details Regarding the Identified Subject Matter
Subject matters	Details	Categories
Health	Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.	Policies or Program
Health, Industry	Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.	Policies or Program
Health	Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries	Policies or Program
Health, Industry	Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.	Regulation
Health, Industry	Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission.	Regulation
Health, Industry	Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines	Regulation
Health, Industry	R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)	Policies or Program, Regulation
Health, Industry	Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.	Policies or Program
Health, Industry	Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)	Policies or Program

Communication Techniques

Written communication
Oral communication

Government Institutions

Atlantic Canada Opportunities Agency (ACOA)
Canadian Heritage (PCH)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Indigenous Services Canada (ISC)
Innovation, Science and Economic Development Canada (ISED)
Natural Resources Canada (NRCan)
Pacific Economic Development Canada (PacifiCan)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)

In-house Corporation Details

Description of activities

Marketing & distribution of pharmaceuticals products.

Responsible officer name and position during the period of this registration

Mark Vineis, Country President

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
700 St-Hubert St., Suite 100
Montreal, QC H2Y 0C1
Canada

Telephone number: 514-631-6775

Parent Company Information

Novartis Holding AG
- Forum 1
  Novartis Campus
  Basel CH-4056
  Switzerland

Subsidiary Beneficiary Information

Novartis Pharmaceuticals Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Mark Vineis, Country President | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Shona Kinley, Director, Public Affairs and Government Relations (Fed-Atlantic) | Public offices held

Novartis Pharmaceuticals Canada Inc.

The following names have been used on or after July 2, 2008

The following names have been used on or after July 2, 2008
Name	From	To
Novartis Pharmaceuticals Canada Inc.	2024-05-01	current
Novartis Pharmaceuticals Canada Inc.	2010-01-04	2024-05-01

The following names have been used before July 2, 2008

Novartis Pharmaceuticals Canada Inc.

Novartis Pharmaceuticals Canada Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Mark Vineis	2024-01-01	Current
Pedro Ferreira	2023-10-01	2024-01-01
Andrea Marazzi	2022-06-01	2023-10-01
Christian Macher	2019-05-01	2022-06-01
Thea Discepola	2019-03-01	2019-05-01
Janice Murray	2017-05-01	2019-03-01
Timothy Maloney	2014-04-01	2017-05-01
Riad Sherif	2011-12-02	2014-04-01
Tom Rossi	2010-01-04	2011-02-02
David Meek	2007-07-13	2008-06-30

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Special Assistant Health Canada, Minister's Office	January 1996 to June 1996	Not a designated office

Date Modified:: 2024-11-13

Search and menus

Language selection

Registration - In-house Corporation

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Country President

Registration Information

Associated Communications

Version 38 of 38 (2024-05-01 to present)

Version 38 of 38 (2024-05-01 to present)

Subject Matter Details

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties